Results 11 to 20 of about 171,176 (147)
Sleep MedicineProlonged nighttime sleep is a prominent symptom in many patients with idiopathic hypersomnia. The only US Food and Drug Administration-approved treatment for idiopathic hypersomnia is low-sodium oxybate (LXB; Xywav®), for which efficacy and safety were established in a double-blind, placebo-controlled, randomized-withdrawal study (NCT03533114).
Anne Marie, Morse +6 more
openaire +3 more sources
Sleep Medicine, 2023 The Transition Experience of persons with Narcolepsy taking Oxybate in the Real-world (TENOR) study assessed the real-world experience of people with narcolepsy switching from sodium oxybate (SXB) to low-sodium oxybate (LXB; 92 % less sodium than SXB).TENOR is a patient-centric, prospective, observational, virtual-format study.
Aatif M, Husain +7 more
openaire +3 more sources
Sialidosis type I: How to alleviate disabling myoclonic seizures?—A multicenter analysis of eight cases and review of the literature [PDF]
Epilepsia Open, Volume 11, Issue 2, Page 577-591, April 2026.Abstract Objective Sialidosis type I (ST‐1) is an autosomal‐recessive, very rare, progressive lysosomal storage disorder caused by pathogenic variants in NEU1. It is clinically characterized by progressive ataxia, myoclonic seizures (MS), bilateral tonic–clonic seizures (BTCS), and distinctive ophthalmological findings.
Janina Gburek‐Augustat +15 more
wiley +2 more sources
Endogenous Levels, Detection Time, and Symptoms of Gamma‐Hydroxybutyric Acid: Results From a Placebo‐Controlled Clinical Trial [PDF]
Basic &Clinical Pharmacology &Toxicology, Volume 137, Issue 6, December 2025.ABSTRACT Gamma‐hydroxybutyric acid (GHB), a potential agent in drug‐facilitated sexual assault, is difficult to detect due to rapid elimination, endogenous presence, and possible postsampling formation. We conducted a randomised, placebo‐controlled trial in 30 healthy volunteers, administering 50‐mg/kg sodium oxybate or placebo, to investigate symptoms,
Kathrine Bohn Faldborg +3 more
wiley +2 more sources
Sleep MedicineLow-sodium oxybate (LXB) is approved in the United States for treating cataplexy or excessive daytime sleepiness in patients aged ≥7 years with narcolepsy and idiopathic hypersomnia in adults. This post hoc analysis evaluated LXB effects on weight in patients with narcolepsy or idiopathic hypersomnia from two phase 3 studies.Adults with narcolepsy with
Nancy, Foldvary-Schaefer +8 more
openaire +3 more sources
Sodium Oxybate-Induced secondary mania with psychotic symptoms: a case report and literature review [PDF]
European PsychiatryIntroduction Sodium oxybate, an effective treatment for narcolepsy-associated daytime sleepiness and cataplexy, has been extensively. Despite its therapeutic benefits, sodium oxybate is not without its risks, and adverse psychiatric effects have been ...
C. Cárdenes Moreno +5 more
doaj +2 more sources
Narcolepsy: Pathophysiology, Diagnosis, Management, and Future Directions, a Narrative Review [PDF]
Brain and Behavior, Volume 15, Issue 12, December 2025.This visual summary outlines the pathophysiology of narcolepsy, driven by hypocretin loss, and details its clinical diagnosis, current management strategies, and the shift toward future disease‐modifying therapies like orexin agonists and immunomodulation.
Natasha Elaine Hastings +12 more
wiley +2 more sources
Future Neurology, 2023 This plain language summary describes a clinical study that looked at the effects of a medicine called low-sodium oxybate (or LXB; XYWAV® [calcium, magnesium, potassium, and sodium oxybates]) in adults with narcolepsy. Narcolepsy is a rare brain disorder
Richard K Bogan +4 more
openaire +2 more sources
Neurology and Therapy, 2023 Narcolepsy is associated with disrupted nighttime sleep (DNS). Sodium oxybate (SXB; Xyrem®), administered twice nightly, is indicated for the treatment of cataplexy and excessive daytime sleepiness in patients 7 years or older with narcolepsy.
Russell Rosenberg +5 more
doaj +1 more source